Atrial Fibrillation Management Emphasizes Modifiable Risk Factors, Flexible Strategies, and Emerging Therapies

Atrial fibrillation (AF), the most common tachyarrhythmia, is rising explosively due to an aging population and increased cardiovascular disease. Current management faces challenges, with mixed results from pharmacological strategies (rate vs. rhythm control). There's a critical need for effective, personalized approaches that consider patient comorbidities and address the reciprocal relationship between maladaptive cardiac remodeling and AF. Early intervention is crucial to prevent modifiable risk factors from becoming unmodifiable.

Researchers reviewed observational cohort studies, systematic reviews, meta-analyses, and randomized controlled trials (RCTs) to identify underlying AF risk factors and treatments. The review specifically focused on comorbid conditions influencing treatment success. The methodology aimed to synthesize existing evidence on AF management, including optimal pharmacological strategies, prevention of thromboembolic events, and the role of novel devices like the Watchman for left atrial appendage occlusion. Emerging therapies, such as GLP-1 agonist medications, were also considered.